In both articles, Src TK activation was shown to be an important mechanism of resistance to HER2 inhibitors, suggesting the potential clinical application of the combined HER2/Src targeting early in the treatment of HER2 positive breast cancers, in order to prevent or overcome resistance to HER2 inhibitors [64, 65]. The gene discussed is ERBB2; the disease is breast cancer.